The European Union (EU) is set to acquire an amount of 110,00 doses of monkeypox vaccines from vaccine manufacturer Bavarian Nordic, which are to be distributed among EU member states, Norway, and Iceland.
Stella Kyriakides, the European Commissioner for Health and Food Safety, made the announcement on Tuesday morning, ahead of a meeting with health ministers from EU member states.
“Funded by #EU4Health, they will be available quickly to Member States most in need,” said Kyriakides in a Tweet.
The monkeypox vaccine acquisition is part of the EU’s European Health Emergency Preparedness and Response Authority (HERA) program, which aims to “Prevent, detect, and rapidly respond to cross-border health emergencies.”
According to Bavarian Nordic, the vaccine distribution will commence immediately and will be finished within the next few months.
Paul Chaplin, CEO of Bavarian Nordic said that the company is “Pleased to enter an agreement with HERA on supplying our vaccine, thus helping to improve the EU readiness and response during the current outbreak of monkeypox throughout Europe.”
The MVA-BN, or Modified Vaccinia Ankara-Bavarian Nordic, is a non-replicating smallpox vaccine that was developed by Bavarian Nordic in collaboration with the United States government.
Bavarian Nordic confirmed that the vaccine was approved by the European Commission in 2013 for immunization against smallpox in adults aged 18 and up.
“HERA now enables a more integrated and coordinated approach across the entire EU, in line with HERA’s mission,” said Chaplin.
The most recent World Health Organization (WHO) update revealed that about 1,300 cases have been verified in countries where monkeypox is not endemic, with the bulk concentrated in Western Europe.
© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.